Why the study?
Does troglitazone improve blood pressure at rest and during mental stress compared to glyburide in patients with type 2 diabetes mellitus?
Does troglitazone improve blood pressure at rest and during mental stress compared to glyburide in patients with type 2 diabetes mellitus?
Troglitazone lowers resting and stress blood pressure in type 2 diabetes by reducing vascular resistance, suggesting that improving insulin resistance provides hemodynamic benefits.
Answers are grounded in this paper and cite their sources.
Troglitazone may improve BP control at rest and during stress in T2DM; extends evidence that insulin sensitization confers hemodynamic benefits.
The present study examined the hemodynamic mechanisms of blood pressure (BP) lowering by troglitazone in patients with type 2 diabetes mellitus (DM) at rest and during a mental arithmetic test (MAT). Twenty-two patients with DM with normal to high-normal BP and 12 controls matched for age, gender, glucose tolerance, and BP were studied. DM subjects showed significantly higher systolic BP response during MAT than controls (157 versus 139 mm Hg; P<0.01). All 22 DM patients and 5 of 12 controls had systolic BP >140 mm Hg during MAT. Heart rate and diastolic BP were not significantly different between the 2 groups. The DM group was then randomized to receive troglitazone (n=10; 400 mg/d) or glyburide (n=12; 20 mg/d). MAT was repeated after 6 months of treatment. Both treatments reduced glucose equally (-1.7 mmol/L for troglitazone and -1.5 mmol/L for glyburide), but only troglitazone reduced insulin (-15 microU/mL; P<0.001) and C-peptide (-0.9 ng/mL; P<0.02) levels. Troglitazone significantly reduced BP at baseline (P<0.05) and systolic BP response to MAT (P<0.01), whereas glyburide did not affect BP at baseline or during MAT. Stroke volume and cardiac output did not change with either drug, but troglitazone decreased peripheral vascular resistance (-112 dyne. s. cm(-5); P<0.05). Improved insulin resistance rather than an improved glycemic control is associated with lower resting and stress BP values in patients with DM. A reduction in vascular resistance may be a primary hemodynamic mechanism of the manner in which troglitazone lowers BP. Insulin sensitizers may offer potential therapeutic advantage in subjects with DM with elevated BP.
No takes yet. Share an insight, caveat, or question.
Sung et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: